We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $44.71 · 17 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
IMVT's Q4 loss wider than expected, stock up 35% on strong study data MSN
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 Moomoo
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
IMVT rockets 35% despite wider loss as arthritis drug shines in study MSN
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock Moomoo
Immunovant Director Sold Shares Worth Over $7.4M - TradingView
Immunovant Director Sold Shares Worth Over $7.4M TradingView
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | After market close (AMC) | $-0.48 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 26. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 23. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 05. 21. | B of A Securities | — | Maintain | Buy → Buy | — | B of A Securities: Buy |
| 2026. 05. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 04. 16. | Goldman Sachs | — | Maintain | Neutral → Neutral | — | Goldman Sachs: Neutral |
| 2026. 02. 10. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,000,000 | $50.84B | 0.08% | — | New position |